Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private

BSE2652.9512.35 (+0.47 %)

PREV CLOSE ( ) 2640.60

OPEN PRICE ( ) 2649.95

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 8748

TODAY'S LOW / HIGH ( )2626.70 2667.60

52 WK LOW / HIGH ( )1910.1 3050

NSE2652.3013 (+0.49 %)

PREV CLOSE( ) 2639.30

OPEN PRICE ( ) 2640.00

BID PRICE (QTY) 2652.30 (30)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 421325

TODAY'S LOW / HIGH( ) 2627.00 2668.90

52 WK LOW / HIGH ( )1901.05 3054.8

Select year

(Rs.in Million)

Particulars

Mar 2025

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Profit Before Tax

25247.80

23993.50

16712.39

19746.01

16916.11

Adjustment

6017.70

2121.90

2984.30

308.07

-56.59

Changes In working Capital

-1464.20

-175.70

1667.29

-5861.21

-946.33

Cash Flow after changes in Working Capital

29801.30

25939.70

21363.98

14192.87

15913.19

Cash Flow from Operating Activities

24133.80

21524.40

18133.02

9197.79

11372.44

Cash Flow from Investing Activities

-126829.50

-20816.90

-10541.29

-13691.44

-12222.11

Cash Flow from Financing Activities

102325.60

52.70

-7397.28

6046.21

-78.11

Net Cash Inflow / Outflow

-370.10

760.20

194.45

1552.55

-927.78

Opening Cash & Cash Equivalents

3820.10

3048.20

2830.60

1273.27

2197.31

Cash & Cash Equivalent on Amalgamation / Take over / Merger

-94.00

Cash & Cash Equivalent of Subsidiaries under liquidations

669.70

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

13.10

11.70

23.15

4.78

3.75

Closing Cash & Cash Equivalent

4038.80

3820.10

3048.21

2830.60

1273.28